Insmed

Insmed is a global biopharmaceutical enterprise dedicated to transforming the lives of patients battling serious and rare pulmonary and inflammatory disorders. The company manufactures Arikayce, an inhaled liposomal antibacterial dispersion for refractory Mycobacterium avium complex lung disease, and is advancing brensocatib for non-cystic fibrosis bronchiectasis. Through specialized drug delivery mechanisms and clinical development, Insmed provides therapeutic options for underserved patient communities.